Table S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
PARP inhibitor and platinum based drugs such as cisplatin are promising therapies for triple negative breast cancer and exploit the deficiencies in BRCA1 or BRCA2, or homologous recombination repair d
Uptake is expressed as % ID/g and presented as an average value from 4 animals ± S.D. “Naive” and “Tumor”, indicate healthy mice and mice challenged with subcutaneous T241 fibrosarcomes, respectively.
In order to identify state changes that mediate the transition from sensitive to a resistant cell states, we applied RNA velocity analysis to an existing single-cell RNAseq (scRNAseq) dataset of BRD4